ABSTRACT The clinical applicability ofthe experimental “proportional reduction ” of dietary phosphorus intake has been evaluated in two groups of patients with chronic renal failure. Forty-five patients with plasma creatinine values of 2.9 to 3.5 mg/dl (glomerular filtration rate 35 to 15 mI/mm) were kept for I to 4 years on a diet containing 40 kcal/kg, about 0.6 g/kg of protein. 600 to 750 mg of phosphorus, and 1500 to 2000 mg ofcalcium (with oral supplementation). Vitamin D or its analogs were prescribed in 7 1 % of the patients. This treatment was effective in preventing the biochemical and morphological (bone biopsy) features of secondary hyperparathyroidism. No metabolic or morphological complications, such as protein depletion or ost...
For Korean dialysis patients, chronic kidney disease–mineral bone disorder is a serious burden becau...
The main purpose of our study was to verify the effect of a very-low-protein, low-phosphorus diet, s...
An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic...
Three groups of patients with chronic renal failure were studied. Group 1 comprised 25 patients with...
Three groups of patients with chronic renal failure were studied. Group 1 comprised 25 patients with...
A diet containing about 40 kcal/kg, 0.6 g/kg of protein, 700 mg of phosphorus, and 1,000 to 1,500 mg...
Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Thr...
On the prevention of secondary hyperparathyroidism in experimental chronic renal disease. Secondary ...
Phosphorus and protein restriction and parathyroid function in chronic renal failure. Phosphorus ret...
Secondary hyperparathyroidism and renal osteodystro-phy are common complications of advanced chronic...
Serum vitamin D metabolites and their relationship with dietary intake of phosphate were evaluated i...
Background and Aim: Elevated serum phosphate and calcium-phosphate levels play an important role in ...
In normal man, the serum phosphate concentration is maintained within a narrow range, despite random...
Although the association between chronic renal failure and bone disease was first recognized 90 year...
Although the association between chronic renal failure and bone disease was first recognized 90 year...
For Korean dialysis patients, chronic kidney disease–mineral bone disorder is a serious burden becau...
The main purpose of our study was to verify the effect of a very-low-protein, low-phosphorus diet, s...
An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic...
Three groups of patients with chronic renal failure were studied. Group 1 comprised 25 patients with...
Three groups of patients with chronic renal failure were studied. Group 1 comprised 25 patients with...
A diet containing about 40 kcal/kg, 0.6 g/kg of protein, 700 mg of phosphorus, and 1,000 to 1,500 mg...
Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Thr...
On the prevention of secondary hyperparathyroidism in experimental chronic renal disease. Secondary ...
Phosphorus and protein restriction and parathyroid function in chronic renal failure. Phosphorus ret...
Secondary hyperparathyroidism and renal osteodystro-phy are common complications of advanced chronic...
Serum vitamin D metabolites and their relationship with dietary intake of phosphate were evaluated i...
Background and Aim: Elevated serum phosphate and calcium-phosphate levels play an important role in ...
In normal man, the serum phosphate concentration is maintained within a narrow range, despite random...
Although the association between chronic renal failure and bone disease was first recognized 90 year...
Although the association between chronic renal failure and bone disease was first recognized 90 year...
For Korean dialysis patients, chronic kidney disease–mineral bone disorder is a serious burden becau...
The main purpose of our study was to verify the effect of a very-low-protein, low-phosphorus diet, s...
An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic...